Provided are novel glucose derivatives and an anticancer agent using the same. The glucose derivatives according to the present invention consist of an L-glucose derivative represented by general formula (1) and a D-glucose derivative represented by general formula (2). In formula (1): XL2 represents an —SAuRL2 group; and XL1, XL3, XL4 and XL5 independently represent an —ORL1 group, an —NH2 group or a fluorine atom. RL2 represents a ligand, and RL1 represents a hydrogen atom or an organic group. In formula (2): XD2 represents an —SAuRD2 group; and XD1, XD3, XD4 and XD5 independently represent an —ORD1 group, an —NH2 group or a fluorine atom. RD2 represents a ligand, and RD1 represents a hydrogen atom or an organic group. The anticancer agent according to the present invention comprises at least one of the aforesaid glucose derivatives.
Provided are: a cancer model animal in which a malignant tumor corresponding to a pathological image of human invasive cancer or metastasis has been formed or can be formed, despite the use of transplantation under the skin or into the abdominal cavity; and a method for producing the cancer model animal. One aspect of the present invention is: a cancer model animal in which tumor cells that grow in a culture medium containing L-glucose are transplanted under the skin or into the abdominal cavity: a sarcoma model animal in which tumor cells that have been transplanted under the skin or into the abdominal cavity invade muscles; a cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show metastasis; or a cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show abnormality of function of orthotopic cells. Another aspect of the present invention is a method for producing a cancer model animal, the method including a step for transplanting a cell composition under the skin or into the abdominal cavity of an animal, the cell composition containing tumor cells that grow by culturing in a culture medium containing L-glucose and being used for producing a cancer model animal by transplanting the cell composition under the skin or into the abdominal cavity of the animal.
Provided are novel glucose derivatives and an anticancer agent using the same. The glucose derivatives according to the present invention consist of an L-glucose derivative represented by general formula (1) and a D-glucose derivative represented by general formula (2). In formula (1): XL2represents an -SAuRL2group; and XL1, XL3, XL4and XL5independently represent an -ORL122 group or a fluorine atom. RL2represents a ligand, and RL1represents a hydrogen atom or an organic group. In formula (2): XD2represents an -SAuRD2group; and XD1, XD3, XD4and XD5independently represent an -ORD122 group or a fluorine atom. RD2represents a ligand, and RD1 represents a hydrogen atom or an organic group. The anticancer agent according to the present invention comprises at least one of the aforesaid glucose derivatives.
Provided is an L-glucose derivative represented by general formula (1). [In formula (1), X1represents a -SAuR1group, and X2, X3, X4, and X5each independently represent a -OR222 group, or a fluorine atom. R1represents a ligand, and R2 represents a hydrogen atom or an organic group.]
A multi-surface image acquisition system includes a multi-surface observation prism which includes one or more prisms and has a light path formed to collect surfaces in respective directions to be observed of a subject having a three-dimensional structure into one direction, in which a light path length is corrected by utilizing a difference in refractive index between glass and air to equalize a working distance of each surface. A light field camera expands a focal-depth adjustment range for two or more images focused on same plane through the prism. A three-dimensional subject can be observed in multiple directions at the same time, including an observation of cells.
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.
A cancer cell detection method that makes it possible to perform imaging of cells in a living state and a dual detection method for cancer cells in which the aforementioned method is combined with a pre-existing dyeing method for cytodiagnosis. The method uses living body-derived cells and includes: incubating living cells included in a sample taken from a person together with a fluorescently-labeled L-glucose derivative and detecting the fluorescently-labeled L-glucose derivative that is taken up into the cells; and detecting fluorescence emitted by the L-glucose derivative that is present within the cells while the cells are attached to a thin glass or plastic plate. Also provided is a dual detection method for cancer cells in which the cancer cell detection method that uses living body-derived cells is combined with a dyeing method using cells that are fixed using an alcohol or the like.
Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided are a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.
C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
The present invention has an object of providing a sugar derivative emitting blue fluorescence color which can be used for imaging of cells or intracellular molecules and a method for imaging cells using the derivative. Further, the present invention has an object of providing a method for detecting cancer cells at high accuracy by imaging, and an imaging agent used for this method. The present invention provides a fluorescently labeled sugar derivative having 3-carboxy-6,8-difluoro-7-hydroxycoumarin or 3-carboxymethyl-6,8-difluoro-7-hydroxy-4-methylcoumarin as a fluorescent molecular group in its molecule, and a cell imaging agent and an imaging method using the derivative. Further, the present invention provides an imaging agent and an imaging method for cancer cells using an L-glucose derivative having the above-described fluorescent molecular group in its molecule.
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C07H 13/10 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C09B 57/00 - Other synthetic dyes of known constitution
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
patents
